What is the eloralintide dosage?
Every vial at a glance.
| Vial | 1 mL of water |
|---|---|
| 10 mg | 10 mg/mL: 1 mg is 10 units, 3 mg is 30 units, 6 mg is 60 units, 9 mg is 90 units |
In the 48-week phase 2 trial by Billings and colleagues (Lancet, 2025) of 263 adults with obesity or overweight without type 2 diabetes, eloralintide was given by subcutaneous injection once a week at 1, 3, 6 or 9 mg, or stepped up to 9 mg, against placebo; Lilly calls it investigational, and searches found no labelled dose.12
Is there an approved eloralintide dose?
Lilly calls eloralintide an investigational once-weekly injectable medication that is being studied for obesity.2 The table above is arithmetic only: no eloralintide vial strength or water volume has been published, so its vial and water values are not a supplied product. Searches of DailyMed, PubMed and ClinicalTrials.gov turned up no label, regulator approval or labelled dose.
Doses and schedule in the trials
The published trials gave eloralintide by subcutaneous injection, once a week in the multiple-dose trials.13
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Billings 2025 (phase 2, NCT06230523) | Subcutaneous, once weekly: 1, 3, 6 or 9 mg, or escalation of 6-9 mg or 3-9 mg, against placebo1 | 263 adults with obesity or overweight, without type 2 diabetes | 48 weeks |
| Bhattachar (phase 1b) | Subcutaneous, once weekly: 1.2 mg, 3 mg, 6 mg or 12 mg, no dose escalation, against placebo3 | One hundred participants with obesity or overweight | 12 weeks |
| Briere (phase 1, NCT05295940) | Single subcutaneous doses from 0.04 to 12 mg, against placebo4 | Forty-eight healthy participants | Single dose, followed to day 29 |
The phase 2 registry entry (NCT06230523) gives the steps: its 6/9 mg arm took 6 mg weekly for 20 weeks and then 9 mg weekly for 28 weeks.5 Its 3/6/9 mg arm took 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks; the Lancet paper calls these two arms 6-9 mg and 3-9 mg.51 The phase 1b authors report a ~14‐day half-life which, with slow absorption, gave relatively flat concentrations over the weekly dosing interval; they gave the doses without dose escalation, unlike other amylin and incretin trials.3
Supply, mixing and storage
No vial strength, tablet strength, concentration, diluent volume or mixing instruction for eloralintide turned up in DailyMed, PubMed, ClinicalTrials.gov or Lilly's FAQ. Without a published concentration, no U-100 syringe mark can be worked for an eloralintide dose. The same searches found no storage condition before or after mixing, no human trial of a powder mixed with water and no stability data. Milligram's logs hold no eloralintide figure at the reporting floor, so no vial or dose share is shown.
Trials now running
ClinicalTrials.gov lists 22 studies matching eloralintide.6 Lilly says it is investigating eloralintide in phase 3 trials.2 One of them, NCT07321886, evaluates efficacy and safety in adults with obesity or overweight without type 2 diabetes, and the registry lists 1980 participants.76 NCT06916065, a completed phase 1 open-label study listed with 188 participants with overweight or obesity, tested single and multiple weekly subcutaneous doses, alone and with tirzepatide.86
Frequently asked questions
What doses do the phase 3 trials use?
The registry entry for NCT07282600, a phase 3 trial in people with overweight or obesity and type 2 diabetes with 1035 participants listed, lists four eloralintide dose arms and a placebo arm without stating the doses; the entry for NCT07321886 also lists Dose 1 to Dose 4 without stating the doses.976
References
- PubMed. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. 2025. pubmed.ncbi.nlm.nih.gov
- Eli Lilly and Company. What to know about eloralintide. lilly.com
- PMC. Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2026. pmc.ncbi.nlm.nih.gov
- PMC. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. 2025. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight. 2026. clinicaltrials.gov
- ClinicalTrials.gov (US National Library of Medicine). ClinicalTrials.gov intervention search: eloralintide. clinicaltrials.gov
- ClinicalTrials.gov. NCT07321886: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes. 2030. clinicaltrials.gov
- ClinicalTrials.gov. NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07282600: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes. 2028. clinicaltrials.gov